Jan van der Meer Selected Research

Thromboembolism

07/2008	Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
03/2005	Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study.
07/2004	The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus.

5	Venous Thromboembolism 02/2007 - 03/2002
3	Thromboembolism 07/2008 - 07/2004
3	Venous Thrombosis (Deep-Vein Thrombosis) 01/2008 - 07/2002
1	Cytomegalovirus Infections (Inclusion Disease) 01/2008
1	Thrombosis (Thrombus) 12/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2006
1	Testicular Neoplasms (Testicular Cancer) 12/2005
1	Liver Diseases (Liver Disease) 08/2005
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2004
1	Activated Protein C Resistance (APC Resistance) 07/2002

3	Factor VIII (Coagulation Factor VIII)IBA 12/2007 - 10/2002
2	Carboxypeptidase U (TAFI)IBA 07/2008 - 10/2002
2	factor V LeidenIBA 10/2002 - 03/2002
1	Oral ContraceptivesIBA 02/2007
1	Prothrombin (Factor II)IBA 10/2006
1	recombinant FVIIa (rFVIIa)IBA 08/2005
1	Protein SIBA 03/2005
1	Vitamin K FDA Link 12/2004
1	Antiphospholipid AntibodiesIBA 07/2004
1	Lipoprotein(a)IBA 10/2002
1	Factor XI (Plasma Thromboplastin Antecedent)IBA 10/2002
1	Carbon MonoxideIBA 10/2002
1	ThrombinIBA 07/2002